Results 151 to 160 of about 184,119 (211)

The flu vaccine in cancer patients: insights from other immune-suppressed populations.

, 2010
Dirk P. Dittmer
openalex   +1 more source

Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches. [PDF]

Bioact Mater
D'Amico C, Fusciello M, Hamdan F, D'Alessio F, Bottega P, Saklauskaite M, Russo S, Cerioni J, Elbadri K, Kemell M, Hirvonen J, Cerullo V, Santos HA.   +12 more
europepmc   +1 more source

Targeting PI3K Signaling to Overcome Tumor Immunosuppression: Synergistic Strategies to Enhance Cancer Vaccine Efficacy. [PDF]

Vaccines (Basel)
Cui R, Luo Z, Zhang X, Yu X, Yuan G, Li X, Xie F, Jiang O.   +7 more
europepmc   +1 more source

Enhancing Cancer Vaccine Efficacy: Backbone Modification with β‑Amino Acids Alters the Stability and Immunogenicity of MUC1-Derived Glycopeptide Formulations. [PDF]

JACS Au
Gibadullin R, Suárez Ó, Lazaris FS, Gutiez N, Atondo E, Araujo-Aris S, Eguskiza A, Niu J, Kuhn AJ, Grosso AS, Rodriguez H, García-Martín F, Marcelo F, Santos T, Avenoza A, Busto JH, Peregrina JM, Gellman SH, Anguita J, Fiammengo R, Corzana F.   +20 more
europepmc   +1 more source

Thermoresistant flagellin-adjuvanted cancer vaccine combined with photothermal therapy synergizes with anti-PD-1 treatment. [PDF]

J Immunother Cancer
Thiruppathi J, Vijayan V, Hwang HS, Bang YJ, Loeurng V, Hong SH, Sundaram A, Park IK, Lee SE, Rhee JH.   +9 more
europepmc   +1 more source

Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure. [PDF]

Cell Rep Med
Gao C, Luo R, Kwong CHT, Liu J, Tang M, Xie B, Duan T, Wang R.   +7 more
europepmc   +1 more source

Innovative therapeutic cancer vaccine PDC^∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer. [PDF]

ESMO Open
Vansteenkiste J, Demedts I, Cuppens K, Pons-Tostivint E, Wauters E, Borm FJ, Sibille A, Colinet B, Pérol M, Theelen WSME, Biesma B, Van De Kerkhove C, Buchmeier E, Althoff FC, Derijcke S, Moro-Sibilot D, Laulagnier K, Halioua E, Levy L, Genin M, Michel S, Dedry C, Duchayne C, Collodoro M, Renard F, Adriaenssens S, De Vos B, Cantero F, Plumas J, Skrzypski M.   +29 more
europepmc   +1 more source

Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study. [PDF]

Future Sci OA
Freitas DMO, Stein AC, Berger M, Kreutz FT.   +3 more
europepmc   +1 more source

Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs. [PDF]

Mol Ther Methods Clin Dev
Meulewaeter S, De Velder M, Reckelbus D, Mwangi K, Ehouarne T, Aernout I, Engelen Y, Halimi F, Van Herteryck I, De Bels L, Redant V, De la Mane L, Ingels J, Coppens B, Van Calenbergh S, Cornillie P, Holtappels G, Descamps B, Vanrompay D, De Smedt SC, Van den Broeck W, Vandekerckhove B, Devreese M, Verbeke R, Lentacker I.   +24 more
europepmc   +1 more source

Activating the dark genome to illuminate cancer vaccine targets. [PDF]

Nat Genet
Kwok DW, Okada H, Costello JF.
europepmc   +1 more source